Skip to main content

Table 4 Clinical Characteristics of Avian Influenza A(H7N9) Case-Patients by Virus Circulation Wave

From: Comparison of the first three waves of avian influenza A(H7N9) virus circulation in the mainland of the People’s Republic of China

 

Total (N,%)

Wave 1 (n, %)

Wave 2 (n, %)

Wave 3 (n, %)

P

Main symptoms at early stage (N1 = 76,N2 = 227,N3 = 169)

 Fever

445(94.3)

74(97.4)

213(93.8)

158(93.5)

0.444

 Cough

386(81.8)

54(71.1)

194(85.5)

138(81.7)

0.019

 Weakness

186(39.4)

29(38.2)

88(38.8)

69(40.8)

0.891

 Muscle soreness

107(22.7)

20(26.3)

53(23.4)

34(20.1)

0.532

 Othersa

170(36)

37(48.7)

70(30.8)

63(37.3)

0.018

Underlying medical conditions (N1 = 74,N2 = 226,N3 = 166)

242(51.9)

43(58.1)

118(52.2)

81(48.8)

0.408

 Cardiovascular and cerebrovascular disease

159(34.1)

29(39.2)

69(30.5)

61(36.8)

0.266

 Metabolic diseases

68(14.6)

12(16.2)

37(16.4)

19(11.5)

0.359

 Chronic lung disease

50(10.7)

12(16.2)

22(9.7)

16(9.6)

0.251

 Chronic liver diseases

32(6.9)

3(4.1)

20(8.9)

9(5.4)

0.241

 Hematological system diseases

14(3.0)

1(1.4)

9(4)

4(2.4)

0.441

 Cancer

10(2.1)

2(2.7)

6(2.7)

2(1.2)

0.580

 Rheumatic autoimmune disease

11(2.4)

5(6.8)

2(0.9)

4(2.4)

0.015

 Immunosuppressive state

12(2.6)

1(1.4)

5(2.2)

6(3.6)

0.529

 Chronic kidney diseases

16(3.4)

1(1.4)

6(2.7)

9(5.4)

0.186

 Nervous system or neuromuscular dysfunction

6(1.3)

0(0)

4(1.8)

2(1.2)

0.500

Complications (N1 = 71,N2 = 219,N3 = 162)

406(89.8)

64(90.1)

197(90)

145(89.5)

0.985

 Pneumonia

392(86.7)

64(90.1)

187(85.4)

141(87.0)

0.585

 Respiratory failure

311(68.8)

47(66.2)

144(65.8)

120(74.1)

0.195

 Acute Respiratory Distress Syndrome(ARDS)

298(65.9)

42(59.2)

141(64.4)

115(71)

0.171

 Hepatic insufficiency

193(42.7)

25(35.2)

90(41.1)

78(48.2)

0.148

 Renal insufficiency

152(33.6)

23(32.4)

68(31.1)

61(37.7)

0.391

 Septic shock

141(31.2)

14(19.7)

64(29.2)

63(38.9)

0.010

 Cardiac failure

124(27.4)

16(22.5)

49(22.4)

59(36.4)

0.006

 Neurologic complications

27(6.0)

2(2.8)

12(5.5)

13(8.0)

0.277

 Disseminated intravascular coagulation

25(5.5)

3(4.2)

9(4.1)

13(8.0)

0.222

 Rhabdomyalysis

17(3.8)

1(1.4)

6(2.7)

10(6.2)

0.115

 Failure of two or more organs

302(66.8)

45(63.4)

139(63.5)

118(72.8)

0.127

  1. N1: Number of individuals in Wave 1 who had clinical information, N2: Number of individuals in Wave 2 who had clinical information, N3: Number of individuals in Wave 3 who had clinical information
  2. aIncluding shortness of breath, chest distress, expectoration, nausea, vomiting, et al